Home Journal of Neurorestoratology Article
Article Link
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript
Show Outline
Outline
Abstract
Keywords
Electronic Supplementary Material
References
Show full outline
Hide outline
Original Research | Open Access

HIF1α/SLC7A11 signaling attenuates 6-hydroxydopamine-induced ferroptosis in animal and cell models of Parkinson’s disease

Xuejia Liua, Zhisheng Hanb, Yuming Huanga, Mingzhi Lia, Jialu Tiana, Shan Zhaoc, Yonghai Lia, Juntang Linb(), Han Lia()
Stem Cells and Biotherapy Engineering Research Center of Henan, National Joint Engineering Laboratory of Stem Cells and Biotherapy, School of Life Science and Technology, Xinxiang Medical University, Xinxiang 453003, Henan, China
Henan Joint International Research Laboratory of Stem Cell Medicine, School of Medical Engineering, Xinxiang Medical University, Xinxiang 453003, Henan, China
Experimental Instruments and Equipment Sharing Service Platform, Xinxiang Medical University, Xinxiang 453003, Henan, China
Show Author Information

Abstract

Background

The pathogenesis of Parkinson’s disease (PD) is associated with ferroptosis. The role of HIF1α is involved in several diseases, but its specific function in PD remains uncertain.

Methods

In this study, we generated animal and cellular models of PD using the neurotoxin 6-OHDA. The occurrence of ferroptosis was determined by measuring levels of ferroptosis-related proteins, Fe2+ amount and transmission electron microscopy analysis in the PD models, and was further confirmed by using a ferroptosis inhibitor. HIF1α overexpressing and HIF1α knockdown SH-SY5Y cells were constructed by lentivirus transfection. Then, the levels of lipid peroxide, ROS, SLC7A11, and GPX4 were detected to elucidate the relationship between HIF1α and ferroptosis. Luciferase assay was used to analyze the regulation between HIF1α and SLC7A11.

Results

We observed a significant downregulation of HIF1α in both animal and cellular PD models. Overexpression of HIF1α mitigated 6-OHDA-induced ferroptosis in SH-SY5Y cells, while, conversely, downregulation of HIF1α promoted ferroptosis in SH-SY5Y cells. BioEdit Sequence Alignment Editor software identified a hypoxia response element (HRE) within the promoter sequence of SLC7A11. The dual-luciferase reporter assays demonstrated that the co-expression of HIF1α and the SLC7A11 promoter significantly augmented reporter activity in SH-SY5Y cells. Moreover, introduction of a mutation into the HRE of the SLC7A11 promoter abolished the induction of SLC7A11 by HIF1α overexpression, resulted in a reduction in promoter activity compared with wild-type cells.

Conclusions

The collective findings of this study indicate that HIF1α can inhibit ferroptosis by positively regulating SLC7A11. This investigation has shed light on the crucial involvement of the HIF1α/SLC7A11 signaling axis in ferroptosis in PD models, thereby presenting patients with PD a promising therapeutic target.

Keywords

Parkinson’s diseaseFerroptosisHIF1αSLC7A11SH-SY5Y

Electronic Supplementary Material

Download File(s)
jnrt-13-1-100171_ESM.docx (710.8 KB)

References

1

Jiang XJ, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266–282. https://doi.org/10.1038/s41580-020-00324-8.

Crossref Google Scholar
2

Chen X, Li JB, Kang R, et al. Ferroptosis: machinery and regulation. Autophagy. 2021;17(9):2054–2081. https://doi.org/10.1080/15548627.2020.1810918.

Crossref Google Scholar
3

Li FJ, Long HZ, Zhou ZW, et al. System xc -/GSH/GPX4 axis: an important antioxidant system for the ferroptosis in drug-resistant solid tumor therapy. Front Pharmacol. 2022;13:910292. https://doi.org/10.3389/fphar.2022.910292.

Crossref Google Scholar
4

Stockwell BR, Angeli JPF, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273–285. https://doi.org/10.1016/j.cell.2017.09.021.

Crossref Google Scholar
5

Yan HF, Zou T, Tuo QZ, et al. Ferroptosis: mechanisms and links with diseases. Signal Transduct Targeted Ther. 2021;6(1):49. https://doi.org/10.1038/s41392-020-00428-9.

Crossref Google Scholar
6

Wang ZL, Yuan L, Li W, et al. Ferroptosis in Parkinson's disease: glia-neuron crosstalk. Trends Mol Med. 2022;28(4):258–269. https://doi.org/10.1016/j.molmed.2022.02.003.

Crossref Google Scholar
7

Xu DC, Chen Y, Xu Y, et al. Signaling pathways in Parkinson's disease: molecular mechanisms and therapeutic interventions. Signal Transduct Targeted Ther. 2023;8:73. https://doi.org/10.1038/s41392-023-01353-3.

Crossref Google Scholar
8

Zhu YQ, Wang B, Tao K, et al. Iron accumulation and microglia activation contribute to substantia nigra hyperechogenicity in the 6-OHDA-induced rat model of Parkinson's disease. Parkinsonism Relat Disorders. 2017;36:76–82. https://doi.org/10.1016/j.parkreldis.2017.01.003.

Crossref Google Scholar
9

Liu J, Zhang C, Zhao YH, et al. Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression. Nat Commun. 2017;8:1823. https://doi.org/10.1038/s41467-017-01947-w.

Crossref Google Scholar
10

Yang Z, Su W, Wei XY, et al. HIF-1α drives resistance to ferroptosis in solid tumors by promoting lactate production and activating SLC1A1. Cell Rep. 2023;42(8):112945. https://doi.org/10.1016/j.celrep.2023.112945.

Crossref Google Scholar
11

Yuan SY, Wei C, Liu GF, et al. Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF-1α/SLC7A11 pathway. Cell Prolif. 2022;55(1):e13158. https://doi.org/10.1111/cpr.13158.

Crossref Google Scholar
12

Mitroshina EV, Vedunova MV. The role of oxygen homeostasis and the HIF-1 factor in the development of neurodegeneration. Int J Mol Sci. 2024;25(9):4581. https://doi.org/10.3390/ijms25094581.

Crossref Google Scholar
13

Xu Q, Guo HL, Zhang XJ, et al. Hypoxia regulation of ATP13A2 (PARK9) gene transcription. J Neurochem. 2012;122(2):251–259. https://doi.org/10.1111/j.1471-4159.2012.07676.x.

Crossref Google Scholar
14

Parsanejad M, Zhang Y, Qu DB, et al. Regulation of the VHL/HIF-1 pathway by DJ-1. J Neurosci. 2014;34(23):8043–8050. https://doi.org/10.1523/JNEUROSCI.1244-13.2014.

Crossref Google Scholar
15

Lin W, Wadlington NL, Chen LN, et al. Loss of PINK1 attenuates HIF-1α induction by preventing 4E-BP1-dependent switch in protein translation under hypoxia. J Neurosci. 2014;34(8):3079–3089. https://doi.org/10.1523/jneurosci.2286-13.2014.

Crossref Google Scholar
16

Millhorn DE, Raymond R, Conforti L, et al. Regulation of gene expression for tyrosine hydroxylase in oxygen sensitive cells by hypoxia. Kidney Int. 1997;51(2):527–535. https://doi.org/10.1038/ki.1997.73.

Crossref Google Scholar
17

Qin LX, Shu L, Zhong JF, et al. Association of HIF1A and Parkinson's disease in a Han Chinese population demonstrated by molecular inversion probe analysis. Neurol Sci. 2019;40(9):1927–1931. https://doi.org/10.1007/s10072-019-03905-4.

Crossref Google Scholar
18

Cahill CM, Sarang SS, Bakshi R, et al. Neuroprotective strategies and cell-based biomarkers for manganese-induced toxicity in human neuroblastoma (SHSY5Y) cells. Biomolecules. 2024;14(6):647. https://doi.org/10.3390/biom14060647.

Crossref Google Scholar
19

Li H, Wei JH, Zhang ZG, et al. Menstrual blood-derived endometrial stem cells alleviate neuroinflammation by modulating M1/M2 polarization in cell and rat Parkinson's disease models. Stem Cell Res Ther. 2023;14(1):85. https://doi.org/10.1186/s13287-023-03330-7.

Crossref Google Scholar
20

Thomas GEC, Zarkali A, Ryten M, et al. Regional brain iron and gene expression provide insights into neurodegeneration in Parkinson's disease. Brain. 2021;144(6):1787–1798. https://doi.org/10.1093/brain/awab084.

Crossref Google Scholar
21

Wang JY, Zhuang QQ, Zhu LB, et al. Meta-analysis of brain iron levels of Parkinson's disease patients determined by postmortem and MRI measurements. Sci Rep. 2016;6:36669. https://doi.org/10.1038/srep36669.

Crossref Google Scholar
22

Van BD, Gouel F, Jonneaux A, et al. Ferroptosis, a newly characterized form of cell death in Parkinson's disease that is regulated by PKC. Neurobiol Dis. 2016;94:169–178. https://doi.org/10.1016/j.nbd.2016.05.011.

Crossref Google Scholar
23

Vallerga CL, Zhang FT, Fowdar J, et al. Analysis of DNA methylation associates the cystineeglutamate antiporter SLC7A11 with risk of Parkinson's disease. Nat Commun. 2020;11:1238. https://doi.org/10.1038/s41467-020-15065-7.

Crossref Google Scholar
24

de Farias CC, Maes M, Bonifácio KL, et al. Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson's disease and its progression: disease and staging biomarkers and new drug targets. Neurosci Lett. 2016;617:66–71. https://doi.org/10.1016/j.neulet.2016.02.011.

Crossref Google Scholar
25

Di Domenico F, Tramutola A, Butterfield DA. Role of 4-hydroxy-2-nonenal (HNE) in the pathogenesis of Alzheimer disease and other selected age-related neurodegenerative disorders. Free Radic Biol Med. 2017;111:253–261. https://doi.org/10.1016/j.freeradbiomed.2016.10.490.

Crossref Google Scholar
26

Mahoney-Sánchez L, Bouchaoui H, Ayton S, et al. Ferroptosis and its potential role in the physiopathology of Parkinson's disease. Prog Neurobiol. 2021;196:101890. https://doi.org/10.1016/j.pneurobio.2020.101890.

Crossref Google Scholar
27

Bi MX, Du XX, Jiao Q, et al. α-synuclein regulates iron homeostasis via preventing parkin-mediated DMT1 ubiquitylation in Parkinson's disease models. ACS Chem Neurosci. 2020;11(11):1682–1691. https://doi.org/10.1021/acschemneuro.0c00196.

Crossref Google Scholar
28

Ayton S, Lei P. Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration. BioMed Res Int. 2014;2014:581256. https://doi.org/10.1155/2014/581256.

Crossref Google Scholar
29

Devos D, Moreau C, Devedjian JC, et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxidants Redox Signal. 2014;21(2):195–210. https://doi.org/10.1089/ars.2013.5593.

Crossref Google Scholar
30

Liu TY, Wang PH, Yin H, et al. Rapamycin reverses ferroptosis by increasing autophagy in MPTP/MPP+-induced models of Parkinson's disease. Neural Regen Res. 2023;18(11):2514–2519. https://doi.org/10.4103/1673-5374.371381.

Crossref Google Scholar
31

Sun YR, He LB, Wang TY, et al. Activation of p62-Keap1-Nrf 2 pathway protects 6-hydroxydopamine-induced ferroptosis in dopaminergic cells. Mol Neurobiol. 2020;57(11):4628–4641. https://doi.org/10.1007/s12035-020-02049-3.

Crossref Google Scholar
32

Sun YR, He LB, Wang W, et al. Activation of Atg7-dependent autophagy by a novel inhibitor of the Keap1-Nrf 2 protein-protein interaction from Penthorum chinense Pursh. attenuates 6-hydroxydopamine-induced ferroptosis in zebrafish and dopaminergic neurons. Food Funct. 2022;13(14):7885–7900. https://doi.org/10.1039/d2fo00357k.

Crossref Google Scholar
33

Li XR, Si WW, Li Z, et al. MiR-335 promotes ferroptosis by targeting ferritin heavy chain 1 in in vivo and in vitro models of Parkinson's disease. Int J Mol Med. 2021;47(4):61. https://doi.org/10.3892/ijmm.2021.4894.

Crossref Google Scholar
34

Zuo Y, Xie JH, Li XC, et al. Ferritinophagy-mediated ferroptosis involved in paraquat-induced neurotoxicity of dopaminergic neurons: implication for neurotoxicity in PD. Oxid Med Cell Longev. 2021;2021:9961628. https://doi.org/10.1155/2021/9961628.

Crossref Google Scholar
35

Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721–732. https://doi.org/10.1038/nrc1187.

Crossref Google Scholar
36

Zheng J, Chen PE, Zhong JF, et al. HIF-1α in myocardial ischemia-reperfusion injury (Review). Mol Med Rep. 2021;23(5):352. https://doi.org/10.3892/mmr.2021.11991.

Crossref Google Scholar
37

Zhou ZY, Wang W, Xiong J, et al. Isoliquiritin apioside relieves intestinal ischemia/reperfusion-induced acute lung injury by blocking Hif-1α-mediated ferroptosis. Int Immunopharm. 2022;108:108852. https://doi.org/10.1016/j.intimp.2022.108852.

Crossref Google Scholar
38

Chen W, Wu PF, Yu F, et al. HIF-1α regulates bone homeostasis and angiogenesis, participating in the occurrence of bone metabolic diseases. Cells. 2022;11(22):3552. https://doi.org/10.3390/cells11223552.

Crossref Google Scholar
39

Packer M. Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics. Am J Kidney Dis. 2021;77(2):280–286. https://doi.org/10.1053/j.ajkd.2020.04.016.

Crossref Google Scholar
40

He QY, Ma YZ, Liu J, et al. Biological functions and regulatory mechanisms of hypoxia-inducible factor-1α in ischemic stroke. Front Immunol. 2021;12:801985. https://doi.org/10.3389/fimmu.2021.801985.

Crossref Google Scholar
41

Green YS, Ferreira dos Santos MC, Fuja DG, et al. ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma. Oncogene. 2022;41:4709–4723. https://doi.org/10.1038/s41388-022-02460-1.

Crossref Google Scholar
42

Liu Y, He LB, Liu BH, et al. Pharmacological inhibition of sphingolipid synthesis reduces ferroptosis by stimulating the HIF-1 pathway. iScience. 2022;25(7):104533. https://doi.org/10.1016/j.isci.2022.104533.

Crossref Google Scholar
43

Wu YH, Wang JK, Zhao TX, et al. Di-(2-ethylhexyl) phthalate exposure leads to ferroptosis via the HIF-1α/HO-1 signaling pathway in mouse testes. J Hazard Mater. 2022;426:127807. https://doi.org/10.1016/j.jhazmat.2021.127807.

Crossref Google Scholar
44

Zou SF, Sun HP, Peng YH, et al. Mu-opioid receptor alleviated ferroptosis in hepatic ischemia-reperfusion injury via the HIF-1α/KCNQ1OT1 axis. Am J Physiol Cell Physiol. 2023;324(4):C927–C940. https://doi.org/10.1152/ajpcell.00394.2022.

Crossref Google Scholar
45

Guan ZY, Jin X, Guan ZQ, et al. The gut microbiota metabolite capsiate regulate SLC2A1 expression by targeting HIF-1α to inhibit knee osteoarthritis-induced ferroptosis. Aging Cell. 2023;22(6):e13807. https://doi.org/10.1111/acel.13807.

Crossref Google Scholar
Journal of Neurorestoratology
Volume 13 Issue 1,
February 2025
DOI: 10.1016/j.jnrt.2024.100171
Cite this article:
Liu X, Han Z, Huang Y, et al. HIF1α/SLC7A11 signaling attenuates 6-hydroxydopamine-induced ferroptosis in animal and cell models of Parkinson’s disease. Journal of Neurorestoratology, 2025, 13(1). https://doi.org/10.1016/j.jnrt.2024.100171
Metrics & Citations  
Article History
Copyright
Rights and Permissions
Return